Search research articles
Contact Us
Filters
Showing results (81-90 of 107) with videos related to
Page
of 11
Sort By:
NPJ Precision Oncology
|
April 17, 2021
Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
Takahiro Yoshizawa, Ken Uchibori, Mitsugu Araki, et al.
Cancer Research
|
February 10, 2019
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of <i>ALK</i> Mutation Status
Koji Fukuda, Shinji Takeuchi, Sachiko Arai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2022
Targeting Podoplanin for the Treatment of Osteosarcoma
Ai Takemoto, Satoshi Takagi, Takao Ukaji, et al.
Leukemia
|
May 26, 2018
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response
Kana Sakamoto, Ryohei Katayama, Reimi Asaka, et al.
Molecular Oncology
|
May 22, 2026
Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr-mutated lung cancer
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 21, 2026
Immune-related gene expression profiling and alectinib efficacy for patients with ALK-Rearranged non-small cell lung cancer: exploratory analysis of a prospective observational study
Takashi Kurosaki, Shinichiro Suzuki, Yasutaka Watanabe, et al.
Science Translational Medicine
|
January 27, 2012
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
Ryohei Katayama, Alice T Shaw, Tahsin M Khan, et al.
Cancer Science
|
March 4, 2025
Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors
Yosuke Miyashita, Ken Tajima, Kenta Izumi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2013
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
Justin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, et al.
Cancer Science
|
June 2, 2026
Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr-Mutant Lung Cancer Mouse Model
Takaaki Tanaka, Masato Fujitani, Masataka Taoka, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 107) with videos related to
Sort By:
Page
of 11
NPJ Precision Oncology
|
April 17, 2021
Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
Takahiro Yoshizawa, Ken Uchibori, Mitsugu Araki, et al.
Cancer Research
|
February 10, 2019
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of <i>ALK</i> Mutation Status
Koji Fukuda, Shinji Takeuchi, Sachiko Arai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2022
Targeting Podoplanin for the Treatment of Osteosarcoma
Ai Takemoto, Satoshi Takagi, Takao Ukaji, et al.
Leukemia
|
May 26, 2018
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response
Kana Sakamoto, Ryohei Katayama, Reimi Asaka, et al.
Molecular Oncology
|
May 22, 2026
Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr-mutated lung cancer
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 21, 2026
Immune-related gene expression profiling and alectinib efficacy for patients with ALK-Rearranged non-small cell lung cancer: exploratory analysis of a prospective observational study
Takashi Kurosaki, Shinichiro Suzuki, Yasutaka Watanabe, et al.
Science Translational Medicine
|
January 27, 2012
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
Ryohei Katayama, Alice T Shaw, Tahsin M Khan, et al.
Cancer Science
|
March 4, 2025
Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors
Yosuke Miyashita, Ken Tajima, Kenta Izumi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2013
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
Justin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, et al.
Cancer Science
|
June 2, 2026
Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr-Mutant Lung Cancer Mouse Model
Takaaki Tanaka, Masato Fujitani, Masataka Taoka, et al.
Page
of 11